Navigation Links
Second breast cancer may be greater than thought for high-risk women without BRCA mutations
Date:5/4/2008

New York, NY A preliminary analysis of ongoing research suggests that high-risk women with breast cancer who do not have a BRCA1/2 mutation may face a greater chance for developing a second breast cancer than previously thought. With the increased risk of cancer in these women, should sentinel node biopsy be considered at the time of prophylactic mastectomy, and how can women best be counseled after these findings?

The increased risk of developing breast cancer is already understood for women with the disease who test positive for a BRCA1 or 2 mutation. Many of these women choose to have their breast(s) surgically removed (prophylactic mastectomy) to reduce their risk of developing breast cancer or developing a second breast cancer The role of sentinel node biopsy remains controversial in this group.

"We know more about counseling women regarding prophylactic mastectomy if they have a BRCA mutation," says Shawna C. Willey, MD, FACS, a member of the Breast Cancer Program at the Lombardi Comprehensive Cancer Center and director of the Betty Lou Ourisman Breast Health Center at Georgetown University Hospital. "In high-risk women who have cancer but dont have a known mutation, we generally advise that the risk of developing a second cancer in the same or opposite breast is lower than it is for women who test positive for a mutation. This latest analysis has us re-thinking our approach."

Willey, the incoming president of the American Society of Breast Surgeons, is the lead author of the study presented today at the societys annual meeting in New York City.

The study included women in a familial cancer registry at Lombardi who were enrolled between 1998 and 2007. The registry participants had a least a 10 percent probability of carrying a BRCA1/2 mutation based on personal or family history of cancer. The cohort for the study included 119 women. 74 women had a BRCA mutation (group 1) and 45 did not test positive for the mutation (group 2). The women in group 2 already had known malignancies and had preoperative genetic testing. All the women opted to have a mastectomy to remove their affected breast (group 2) or surgery to remove both breasts (both groups). They all had both breasts removed, but in Group 2 they all had a unilateral prophylactic mastectomy.

"We examined the rate of occult malignancies in both these groups of women in the prophylactic mastectomy specimens," Willey explains. "What we found was interesting. There was a higher than expected presence of disease in the women who did not test positive for a BRCA mutation.

"The higher rate of occult cancers in group 2 may be because they all had contralateral known malignancies, but this study supports the use of prophylactic mastectomy as an option for these women as it is for those who have a BRCA mutation," says Willey.

Willey notes that additional studies should address the role of sentinel node biopsy for high-risk women who are receiving prophylactic mastectomy.

"We need a better understanding of the incidence of cancer in these women to help determine the need for sentinel lymph node biopsy at the time of mastectomy, even in patients in which mastectomy is entirely prophylactic," says Willey. "There are risks and serious side effects involved with sentinel node biopsy. We will need to find a balance between offering appropriate care and over-treating these women.

"The trend in this study highlights the importance of counseling all high-risk women about their risk of developing another cancer when considering surgical options including sentinel node biopsy."


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
414-312-7085
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. 9/11 Counselors at Risk for Secondary Trauma
2. American Pacific to Release Financial Results and Hold Fiscal 2008 Second Quarter Investor Teleconference
3. CryoCath to Hold Second Quarter 2008 Conference Call and Webcast
4. Landauer, Inc. Reports Record Results for Second Quarter
5. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2008 Second Quarter Earnings Webcast
6. NBTY Reports Second Quarter Results
7. Aflac Incorporated Announces First Quarter Results, Declares Second Quarter Cash Dividend
8. BD Announces Results for Second Fiscal Quarter
9. Study: Counseling trauma victims causes secondary trauma
10. Lilly Declares Second-Quarter Dividend
11. NBTY to Web Cast Fiscal Second Quarter Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... planning services and products in the developing world, is pleased to release their ... prevent over 5 million unwanted pregnancies, almost 14,000 maternal deaths and 3.8 million ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... Clearinghouse supporting the real time adjudication of medical service claims by Pharmacy Benefit ... their current medical claims management software. The TransactRx Cross Benefit Clearinghouse receives standard ...
(Date:5/25/2016)... ... , ... The University of San Francisco (USF) has named Margaret Wooding Baker ... of more than 100 full-time faculty and staff, and serve as a member of ... , Baker comes to USF from the University of Washington in Seattle, where she ...
(Date:5/25/2016)... ... May 25, 2016 , ... Laser Skin & Wellness Center ... hands of time of female aging. The Juliet™ procedure helps to ... such as leakage, laxity, itchiness and pain have reported real relief from these and ...
(Date:5/25/2016)... ... May 25, 2016 , ... Researchers from SUNY State ... Meeting for their work on visual evoked potential and human attention. The article, ... used the Diopsys® NOVA™ ERG and VEP Vision Testing System (Diopsys, Inc., ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016   , Study ... overall bowel cleansing and superiority in , ... of the ascending colon ... Norgine B.V. today announced new positive data from the ... bowel preparation) versus standard 2 litre PEG with ascorbate. The study ...
(Date:5/24/2016)... N.J. , May 24, 2016 ... oncology drug development company, today provided an update ... dose escalating clinical trial combining GEN-1, the Company,s ... the treatment of newly-diagnosed patients with advanced ovarian ... interval debulking surgery.  GEN-1 is an IL-12 DNA ...
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse ... cathéters destinés à l,intervention portant sur les ...   OrbusNeich, entreprise mondiale spécialisée ... de changer la vie, a élargi son ...
Breaking Medicine Technology: